D/SB/21 (09(04)

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

OIPE	Application Number	10/751,009				
TRANSMITTAL S	Filing Date	December 3	31, 2003			
FOR M JAH 1 8 2005 %	First Named Inventor	Samuel P. I				
	Art Unit	1624				
(to be used for all correspondence that initial flats)	Examiner Name	Unassigned]			
Total Number of Pages in This Submission	Attorney Docket Number	SHE0074.0	0			
	<u> </u>					
ENC	LOSURES (Check a	ll that apply)				
Fee Transmittal Form	Drawing(s)			Allowance Communication to TC		
Fee Attached	Licensing-related Papers	<u> </u>	ا of Ap	al Communication to Board peals and Interferences		
Amendment/Reply	Petition Petition to Convert to a			al Communication to TC al Notice, Brief, Reply Brief)		
After Final	Provisional Application Power of Attorney, Revocati		_ Propr	ietary Information		
	Change of Correspondence		_	s Letter		
Extension of Time Request	Terminal Disclaimer		below ل	•		
	Request for Refund	110	ited Ref	ference		
X Information Disclosure Statement	CD, Number of CD(s)					
	Landscape Table on C	:D 0:				
Certified Copy of Priority Document(s)	rks	<u> </u>				
Reply to Missing Parts/						
Incomplete Application Reply to Missing Parts						
under 37 CFR 1.52 or 1.53						
	OF APPLICANT, ATTO	DRNEY, OR A	GENT			
Firm Name NEKTAR THERAPEUTI	CS					
Signature Mark a. Wits						
Printed name Mark A. Wilson						
Date Junuary 7, 2004 Reg. No. 43,275						
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on						
the date shown below: Signature						
Typed or printed name Minna Cotter			Date	01/07/2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U,S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

JAN 1 8 2005 G

THE UNITED STATES PATENT AND TRADEMARK OFFICE

<u>In re</u> the applicati al.	on of: Samuel P. McManus et)	Atty. Docket No.:	SHE0074.00
))	Examiner: Unassi	igned
Application No.:	10/751,009))	Group Art Unit: 1	624
Filed: 12/31/200	3)		
	ER DERIVATIVES AND ATES THEREOF)))		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on January 7, 2005

Signed: Musica Cetter

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The reference listed in the attached Form PTO/SB/08B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

A copy of the reference is enclosed, as required under 37 CFR §§1.98.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

Attorney Docket No. SHE0074.00

		the date of entry of	the nation	ling date of a national application; within three months of nal stage as set forth in section 1.491 in an international illing date of a first Office action on the merits (whichever	
	Please	charge the amount of	of <u>\$</u> to	Deposit Account 500348	
		If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.			
				Respectfully submitted,	
				NEKTAR THERAPEUTICS	
Dated:	_Jan	ugny 7, 2005	Ву:	Mark Wilson Reg. No. 43,275	
	arlos, C. 531-310	A 94070 00			

IAN 1 0 2005	8		
Form PTO/SB/08B (Modified)	ty Docket No.:	Application No.:	
William - will	SHE0074.00	10/751,009	
Information Disclosure	Applicant:		
Statement By Applicant	Samuel P. McManus et al.		
	Filing Date:	Group:	
(Use Several Sheets if Necessary)	12/31/2003	1624	

Other Documents

	·	r	
Examiner			
Initial		NI.	Andhan (Pala Data Diana (. I . D. CD 11)
Initial		No.	Author, Title, Date, Place (e.g. Journal) of Publication
		BW	Shearwater Polymers, Inc., Catalog 2000: Polyethylene Glycol and Derivatives,
		- ''	Employed and Delivatives,
]		Functionalized Biocompatible Polymers for Research and Pharmaceuticals,
			Huntsville, AL, pp. 1-50.
	<u> </u>		
	_		
	_		
	_		
	_		
	_		
	_		
	_		
	-		
	\vdash		
	_	_	
	$oxed{L}$		
	_ '		
· · · · · · · · · · · · · · · · · · ·			
	Ш		

Examiner:	Date Considered:	

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.